Home >
Publications/Products > HIV/Hepatitis C Coinfection Guidelines
for Health Care Providers
Table 8. Virologic Response Rates in the APRICOT Study
Back to Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
| INF alfa-2a 3 MIU. tiw + RBV 800 mg/day x 48 wk | Peg INF alfa-2a (PEGASYS) 180 µg/wk + placebo x 48 wk | Peg INF alfa-2a (PEGASYS) 180 µg/wk + RBV 800 mg/day x 48 wk | |
|---|---|---|---|
| *p = 0.0078 versus IFN + RBV; ** p < 0.0001 versus IFN + RBV, p < 0.0001 versus PEG only. | |||
| n = 285 | n = 286 | n = 289 | |
| ETR (Overall) | 14% | 33% | 49% |
| Genotype 1 | 8% | 21% | 38% |
| Non-Genotype 1 | 27% | 57% | 64% |
| SVR (Overall) | 12% | 20%* | 40%** |
| Genotype 1 | 7% | 14% | 29% |
| Non-Genotype 1 | 20% | 36% | 62% |
From Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
Hepatitis C Resource Center Program and National Hepatitis C Program Office
September 2005
